Atrogi announces first subjects dosed in human trial for lead candidate ATR-258

Atrogi AB Denmark Sweden

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with broad potential as a novel treatment for muscle-sparing weight lossStudy led by Associate Professor Morten Hostrup, a leading authority on ?2-adrenergic receptor signaling in skeletal muscle at the University of Copenhagen, to evaluate muscle physiological aspects of ATR-258's highly selective ?2-adrenergic signalingAtrogi's breakthrough technology, validated by publication of landmark research in Cell in June 2025, enables, for the first time, development of next-generation, highly selective ?2-agonists for chronic usewhich validated Atrogi's novel GRK2-biased signaling pathway approach, unlocking the therapeutic potential of muscle-targeted ?2-agonists while avoiding the cardiovascular side effects typically associated with this approach. The paper also detailed first-in-human trial data from a 69-subject Phase 1 trial, demonstrating the safety and tolerability of ATR-258 in both healthy volunteers and patients with type 2 diabetes.

Paul Little, Chief Executive Officer at Atrogi, commented: "The initiation of this study, and dosing of the first subjects, marks an important milestone for Atrogi. With safety established in Phase 1 and a validated mechanism of action, the generation of key muscle physiology data from this trial will underpin ATR-258's further development across metabolic and muscle-wasting conditions."

Additional information on the study for ATR-258 can be found on www.clinicaltrials.gov, NCT identifier NCT07421024.

About Atrogi

Atrogi AB is a Stockholm-based, clinical-stage biotech pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health. Its lead candidate, ATR-258, is a first-in-class oral GRK2-biased ?2-agonist designed to safely stimulate muscle metabolism and preserve lean mass, offering a novel approach to treating diabetes, obesity, and muscle loss.

Atrogi's proprietary compound library, developed under the scientific leadership of Professor Tore Bengtsson, serves as the foundation for a broader platform aimed at discovering selective GPCR modulators across multiple disease areas. Learn more at www.atrogi.com and on LinkedIn.

View original content:https://www.prnewswire.co.uk/news-releases/atrogi-announces-first-subjects-dosed-in-human-trial-for-lead-candidate-atr-258-302716298.html